Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.

about

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.

Item

http://www.wikidata.org/entity/Q48122799

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Patient characteristics influe ...... e harmful than TNFi biologics.

@en

Patient characteristics influe ...... e harmful than TNFi biologics.

@nl

type

Item

label

Patient characteristics influe ...... e harmful than TNFi biologics.

@en

Patient characteristics influe ...... e harmful than TNFi biologics.

@nl

prefLabel

Patient characteristics influe ...... e harmful than TNFi biologics.

@en

Patient characteristics influe ...... e harmful than TNFi biologics.

@nl

P1476

Patient characteristics influe ...... re harmful than TNFi biologics

@en

P2093

ARTIS Study group

http://www.w3.org/2001/XMLSchema#string

Daniela Di Giuseppe

http://www.w3.org/2001/XMLSchema#string

Eva Baecklund

http://www.w3.org/2001/XMLSchema#string

Johan Askling

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data.

How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?

External review and validation of the Swedish national inpatient register.

Use of comorbidity scores for control of confounding in studies using administrative databases.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.

Swedish registers to examine drug safety and clinical issues in RA.

Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study

The completeness of the Swedish Cancer Register: a sample survey for year 1998.

P304

650-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2017-212395

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Frisell

Helena Forsblad-d'Elia

Karin Bengtsson

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29237621

http://www.w3.org/2001/XMLSchema#string

P932

5909744

http://www.w3.org/2001/XMLSchema#string